NEWPORT BEACH, Calif., July 23, 2026 (KOREWIRE) — ICON Capital Group, LLC (“ICON”), a boutique investment banking firm specializing in capital formation and strategic advisory services, today announced the successful completion of a $4.2 million growth financing for Watershed Medical, an emerging medical technology company developing innovative drug delivery solutions for bladder cancer and other urological indications. ICON served as the broker-of-record for the transaction.

The financing round was led by MedTech Syndicates, a leading investor network focused on breakthrough medical technology companies, with participation from a group of strategic healthcare investors and industry stakeholders.

Watershed Medical is advancing a proprietary intravesical drug delivery platform designed to improve treatment outcomes, patient compliance, and quality of life for patients suffering from bladder cancer and other urologic diseases. The company’s technology is engineered to provide sustained therapeutic delivery directly to the bladder while addressing key challenges associated with conventional treatment approaches.

“This successful capital raise represents a significant milestone for Watershed Medical as the company accelerates development of its innovative platform,” said John Calicchio, Chief Executive Officer of ICON Capital Group. “We are proud to have served as broker-of-record and to have worked alongside MedTech Syndicates to connect Watershed with investors who recognize the tremendous clinical and commercial potential of its technology.”

The proceeds from the financing will support continued product development, regulatory advancement, clinical initiatives, and expansion of Watershed Medical’s commercialization strategy.

“Completing this financing positions Watershed Medical to execute on several key milestones and continue advancing solutions that have the potential to meaningfully improve patient outcomes,” said Topher Kinsella, CEO of Watershed Medical. “We appreciate the support of MedTech Syndicates, ICON Capital Group, and our investor group as we enter this next phase of growth.”

“Watershed Medical exemplifies the type of innovative medical technology company we seek to support,” said a representative of MedTech Syndicates. “We believe the company’s platform addresses a significant unmet need and offers compelling opportunities to improve patient care in large and growing markets.”

The transaction further underscores ICON Capital Group’s commitment to supporting innovative healthcare and life sciences companies through strategic capital formation and advisory services.

About Watershed Medical

Watershed Medical is a medical technology company focused on developing next-generation intravesical drug delivery solutions for bladder cancer and other urological indications. The company’s proprietary platform is designed to deliver sustained therapeutic benefits while improving patient experience and treatment effectiveness. For more information, visit www.watershedtx.com.

About MedTech Syndicates

MedTech Syndicates is an investor network focused on identifying, funding, and supporting innovative medical technology companies that are advancing patient care through breakthrough technologies and clinical innovation.

About ICON Capital Group, LLC

ICON Capital Group, LLC is a full-service boutique investment banking firm specializing in custom financial solutions for emerging growth and middle-market companies. The firm provides capital formation, mergers and acquisitions advisory, strategic consulting, and corporate finance services across a range of industries, including healthcare, life sciences, technology, and industrial sectors. For more information, visit www.iconcapg.com.

Media Contact
Calibou Group, Inc.
Investor Relations
info@calibougroup.com

About The Author
KoreWire